Edition:
India

Abiomed Inc (ABMD.OQ)

ABMD.OQ on NASDAQ Stock Exchange Global Select Market

423.48USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$423.48
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
300,589
52-wk High
$450.93
52-wk Low
$141.59

Latest Key Developments (Source: Significant Developments)

Abiomed Announces European Approval For Impella 5.5(Tm)
Thursday, 5 Apr 2018 

April 5 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG.  Full Article

Abiomed Says Entered Settlement With U.S. DoJ Resolving Claims Related To Employee Meals
Friday, 9 Mar 2018 

March 8 (Reuters) - Abiomed Inc ::ABIOMED - ON MARCH 6, ENTERED SETTLEMENT WITH U.S. DOJ RESOLVING CLAIMS ON CO'S REIMBURSEMENT OF EMPLOYEE EXPENSES FOR MEALS WITH HEALTHCARE PROVIDERS.  Full Article

Abiomed Reports Preliminary Q3 FY 2018 Revenue Of $154 Mln, Up 34 Pct Over Prior Year
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Abiomed Inc ::ABIOMED ANNOUNCES PRELIMINARY Q3 FY 2018 REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR.Q3 REVENUE $154 MILLION VERSUS I/B/E/S VIEW $147.9 MILLION.  Full Article

Abiomed Q2 earnings per share $0.54
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Abiomed Inc :Abiomed announces Q2 fy 2018 revenue of $132.8 million, up 29% and record u.s. Patient utilization, up 33 pct.Q2 gaap earnings per share $0.54.Q2 revenue $132.8 million versus I/B/E/S view $131.1 million.Q2 earnings per share view $0.38 -- Thomson Reuters I/B/E/S.Abiomed Inc - ‍is increasing lower end of its fiscal year 2018 revenue guidance by $5 million to a new range of $565 million to $575 million​.FY 2019 revenue view $727.3 million -- Thomson Reuters I/B/E/S.Abiomed Inc - ‍increasing its fiscal year 2018 guidance for gaap operating margin to range of 23 pct to 25 pct, from 22 pct to 24 pct​.  Full Article

Abiomed maintains fiscal year 2018 revenue guidance
Tuesday, 29 Aug 2017 

Aug 28 (Reuters) - Abiomed Inc :Says ‍is maintaining its fiscal year 2018 revenue guidance of $560 million to $575 million - SEC filing​.Says is ‍maintaining its fiscal year 2018 guidance for GAAP operating margin in range of 22% to 24%​.FY2018 revenue view $573.8 million -- Thomson Reuters I/B/E/S.  Full Article

ABIOMED says CFO Michael Tomsicek resigns
Tuesday, 29 Aug 2017 

Aug 28 (Reuters) - ABIOMED Inc :ABIOMED announces resignation of chief financial officer and welcomes back former chief financial officer as consultant.Says CFO Michael Tomsicek resigned.ABIOMED Inc - ‍Former CFO, Robert Bowen, will return from retirement to support organization as a consultant until a new CFO has been recruited​.ABIOMED-‍Ian Mcleod to perform functions of principal financial officer, principal accounting officer on interim basis until permanent cfo has been hired​.  Full Article

Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare
Tuesday, 27 Sep 2016 

Abiomed Inc : Abiomed Impella 2.5 and Impella 5.0 heart pumps receive regulatory approval from Japan Ministry of Health, Labor & Welfare . Co planning future discussions with PMDA relating to potential regulatory reviews of Impella CP and Impella RP later this fiscal year . Plans to start supporting patients in Japan during Q4 of FY '17 . Company will conduct a post-market surveillance on Impella usage .Says does not expect material revenue until FY'18.  Full Article

BRIEF-Abiomed Q4 GAAP EPS $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR